Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Lung Cancer
Anti-TIGIT Antibody Tiragolumab plus Atezolizumab in Patients with PD-L1–Selected NSCLC
Read More
Lung Cancer
Phase 3 EMPOWER-Lung 1 Study of Cemiplimab in Advanced PD-L1–Positive NSCLC
Read More
Lung Cancer
Updated Analysis of PFS Data from Cohort G of KEYNOTE-021 in Nonsquamous NSCLC
Read More
Lung Cancer
Durvalumab Demonstrates Sustained Overall Survival in Unresectable Stage III NSCLC
Read More
Lung Cancer
ADAURA Results: Osimertinib as Adjuvant Therapy for EGFR-Mutated NSCLC
Read More
Lung Cancer
Neoadjuvant Nivolumab plus Chemotherapy Achieves Promising Responses in Resectable NSCLC (CheckMate-816)
Read More
Lung Cancer
Adjuvant Gefitinib versus Vinorelbine plus Cisplatin in Patients with Completely Resected Stage II to IIIA EGFR-Mutant NSCLC (ADJUVANT)
Read More
Lung Cancer
Stereotactic Body Radiotherapy versus Delayed Surgery for Early-Stage NSCLC
Read More
Lung Cancer
3-Year Follow-Up Data for Nivolumab Combined with Ipilimumab in Treatment-Naïve NSCLC: CheckMate-227
Read More
Lung Cancer
Combination of Chemotherapy with Nivolumab plus Ipilimumab in First-Line Advanced NSCLC (CheckMate-9LA)
Read More
6
7
8
9
10
11
12
Page 9 of 12
Results 81 - 90 of 114